Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 7/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204474 | 0.84 | KCNH2 (0.42) | MPLHSD11B1FEN1ALOX5APCYP1A2 | |
| SCHEMBL2615844 | 0.83 | HSD11B1 (0.43) | HSD11B1CYP1A2PDE2AGRM2 | |
| SCHEMBL18908816 | 0.81 | MPL (0.48) | MPLHSD11B1FEN1ALOX5APAPP | |
| SCHEMBL2131399 | 0.81 | MPL (0.57) | MPLHSD11B1FEN1ALOX5APIDO1 | |
| SCHEMBL25400896 | 0.80 | TP53 (0.48) | FEN1ALOX5APCYP1A2PDE2A | |
| SCHEMBL2609368 | 0.80 | MPL (0.47) | MPLHSD11B1FEN1ALOX5APAPP | |
| SCHEMBL13265493 | 0.80 | CYP1A2 (0.39) | MPLHSD11B1FEN1ALOX5APCYP1A2 | |
| SCHEMBL31399815 | 0.80 | TP53 (0.48) | FEN1ALOX5APCYP1A2PDE2A | |
| SCHEMBL13273285 | 0.80 | ALPL (0.43) | CYP11B2CYP11B1 | |
| SCHEMBL2615352 | 0.77 | KMO (0.43) | HSD11B1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785445-B2 | 7-phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2010075200-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | PTGDR2, PTGDR, HRH2 | MPL 1072/4885HSD11B1 541/4885FEN1 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.